Display options
Cite
Chia BSH, Nei WL, Charumathi S, et al. Baseline Plasma EGFR Circulating Tumour DNA Levels in a Pilot Cohort of EGFR-Mutant Limited-Stage Lung Adenocarcinoma Patients Undergoing Radical Lung Radiotherapy. Case Rep Oncol. 2020;13(2):896-903doi: 10.1159/000508932.
Chia, B. S. H., Nei, W. L., Charumathi, S., Fong, K. W., & Tan, M. H. (2020). Baseline Plasma EGFR Circulating Tumour DNA Levels in a Pilot Cohort of EGFR-Mutant Limited-Stage Lung Adenocarcinoma Patients Undergoing Radical Lung Radiotherapy. Case reports in oncology, 13(2), 896-903. https://doi.org/10.1159/000508932
Chia, Brendan Seng Hup, et al. "Baseline Plasma EGFR Circulating Tumour DNA Levels in a Pilot Cohort of EGFR-Mutant Limited-Stage Lung Adenocarcinoma Patients Undergoing Radical Lung Radiotherapy." Case reports in oncology vol. 13,2 (2020): 896-903. doi: https://doi.org/10.1159/000508932
Chia BSH, Nei WL, Charumathi S, Fong KW, Tan MH. Baseline Plasma EGFR Circulating Tumour DNA Levels in a Pilot Cohort of EGFR-Mutant Limited-Stage Lung Adenocarcinoma Patients Undergoing Radical Lung Radiotherapy. Case Rep Oncol. 2020 Jul 29;13(2):896-903. doi: 10.1159/000508932. eCollection 2020. PMID: 32884537; PMCID: PMC7443655.
Copy Download .nbib Format: NLM
Share it on

Case Rep Oncol. 2020 Jul 29;13(2):896-903. doi: 10.1159/000508932. eCollection 2020.

Baseline Plasma EGFR Circulating Tumour DNA Levels in a Pilot Cohort of EGFR-Mutant Limited-Stage Lung Adenocarcinoma Patients Undergoing Radical Lung Radiotherapy.

Case reports in oncology

Brendan Seng Hup Chia, Wen Long Nei, Sabanayagam Charumathi, Kam Weng Fong, Min-Han Tan

Affiliations

  1. Division of Radiation Oncology, National Cancer Centre Singapore, Singapore, Singapore.
  2. Centre for Quantitative Medicine, Duke-NUS Medical School, Singapore, Singapore.
  3. Institute of Bioengineering and Nanotechnology, ASTAR Singapore, Singapore, Singapore.

PMID: 32884537 PMCID: PMC7443655 DOI: 10.1159/000508932

Abstract

The use of circulating cell-free tumour DNA (ctDNA) is established in metastatic lung adenocarcinoma to detect and monitor sensitising EGFR mutations. In early-stage disease, there is very little data supporting its role as a potential biomarker. We report on a prospective cohort of 9 limited-stage EGFR mutant lung cancer patients who were treated with radical radiotherapy. We looked at baseline plasma EGFR ctDNA and noted the detection rates to be higher in locally advanced disease. At a median follow-up of 13.5 months, an association between a detectable pre-radiotherapy plasma EGFR ctDNA and early tumour relapse (155 days vs. NR,

Copyright © 2020 by S. Karger AG, Basel.

Keywords: Biomarker; Circulating tumour DNA; Lung adenocarcinoma; Plasma EGFR; Prognosis

Conflict of interest statement

Min-Han Tan is the founding CEO and Medical Director of Lucence Diagnostics. All remaining authors have declared no conflicts of interest.

References

  1. Cancer. 2014 Dec 15;120(24):3896-901 - PubMed
  2. JAMA Oncol. 2015 May;1(2):149-57 - PubMed
  3. Thorac Cancer. 2018 Sep;9(9):1104-1110 - PubMed
  4. Sci Rep. 2016 Sep 19;6:33519 - PubMed
  5. ESMO Open. 2018 Feb 8;3(2):e000292 - PubMed
  6. Curr Respir Med Rev. 2018 Mar;14(1):48-60 - PubMed
  7. J Thorac Cardiovasc Surg. 2017 Sep;154(3):1123-1131.e2 - PubMed
  8. Clin Cancer Res. 2014 Mar 15;20(6):1698-1705 - PubMed
  9. Sci Transl Med. 2014 Feb 19;6(224):224ra24 - PubMed
  10. Oncotarget. 2017 May 10;8(39):65111-65122 - PubMed
  11. J Thorac Dis. 2018 Apr;10(Suppl 7):S876-S881 - PubMed
  12. Nature. 2017 Apr 26;545(7655):446-451 - PubMed
  13. Oncotarget. 2016 Nov 29;7(48):78985-78993 - PubMed
  14. Clin Cancer Res. 2015 Jul 15;21(14):3196-203 - PubMed
  15. BMC Med. 2018 Oct 2;16(1):166 - PubMed
  16. Cancer Discov. 2017 Dec;7(12):1394-1403 - PubMed
  17. Science. 2018 Feb 23;359(6378):926-930 - PubMed
  18. JAMA Oncol. 2016 Aug 1;2(8):1014-22 - PubMed
  19. Clin Transl Med. 2019 Jan 19;8(1):4 - PubMed
  20. Clin Cancer Res. 2016 Dec 15;22(24):6010-6020 - PubMed
  21. Nat Med. 2014 May;20(5):548-54 - PubMed
  22. Cancer Med. 2017 May;6(5):962-974 - PubMed

Publication Types